Ignite Creation Date:
2024-05-05 @ 11:18 PM
Last Modification Date:
2024-10-26 @ 10:32 AM
Study NCT ID:
NCT01301898
Status:
COMPLETED
Last Update Posted:
2012-02-14
First Post:
2011-02-22
Brief Title:
To Evaluate the Safety and Efficacy of GC1111 Recombinant Human Iduronate-2-sulfatase in Hunter Syndrome Patients
Sponsor:
Green Cross Corporation
Organization:
GC Biopharma Corp
Study Overview
Official Title:
Randomized Single-blind Active-controlled Phase 12 Study to Evaluate the Safety and Efficacy of GC1111 Recombinant Human Iduronate-2-sulfatase in Hunter Syndrome Mucopolysaccharidosis II Patients
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of GC1111 recombinant human iduronate-w-sulfatase in Hunter Syndrome Mucopolysaccharidosis II patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None